NEW YORK, Sept. 20, 2012  /PRNewswire/ -- Reportlinker.com announces that a new market research report is available in its catalogue:

Central Nervous System Drug Delivery Specialists

http://www.reportlinker.com/p0968547/Central-Nervous-System-Drug-Deliver...

The blood-brain barrier (BBB) is so effective at limiting the passage of exogenous substances that many drugs with the potential to treat CNS diseases are rendered ineffective by their inability to reach their target. Consequently, companies that develop innovative delivery technologies are in a position to play a vital role in CNS drug development.Identify the leading companies with innovative technologies designed to enhance CNS drug delivery.Compare the technologies that each company has developed and the diseases to which they are being applied.Evaluate each company's pipeline of products and the intellectual property on which these are based.Assess the alliances that have been formed to maximize the opportunities for commercial exploitation of the innovations.Many drug delivery specialists have developed novel technology platforms to improve the passive or active transport of therapeutics across the blood-brain barrier through the encapsulation of drugs within liposomes (ArmaGen Technologies, Corden Pharma Switzerland), bolaamphiphilic vesicles (Lauren Sciences), and nanoparticles (to-BBB Technologies).There has been success in circumventing the BBB by developing biodegradable implants (Durect Corporation) and programmable infusion devices (DePuy, Flowonix, Medtronic) for the localized delivery of drugs.Intranasal delivery, which allows direct nose-to-brain access through the olfactory region, holds much promise. Medical device companies Kurve Technology, Impel NeuroPharma, and OptiNose have all developed devices that are compatible with intranasal delivery, and several products are now under evaluation.Which companies are at the cutting-edge of CNS drug delivery technology?How extensive are the patent portfolios supporting the company's innovations?What alliances have been formed to accelerate the commercial exploitation of the delivery technologies?What are the prospects of success for each company's technological innovations?

EXECUTIVE SUMMARY•Key findings

Drug delivery specialists, strategic alliances, and intellectual property•Leading companies - Alkermes

- Angiochem

- ArmaGen Technologies

- biOasis Technologies

- Corden Pharma Switzerland LCC

- D-Pharm

- Durect Corporation

- Flowonix Medical

- Impel NeuroPharma

- Kurve Technology

- Lauren Sciences

- Medtronic

- OptiNose

- Raptor Pharmaceutical Corporation

- to-BBB Technologies BV

•Conclusions

Appendix•Scope

•Methodology - Acknowledgements

•Abbreviations•Bibliography/referencesTABLES•Table: Innovative drug delivery specialists targeting unmet clinical need in the CNSCompanies MentionedAlkermes plc, Arriva plc, Avista Corporation, Business Development Bank of Canada, DURECT Corporation, First Aviation Services Inc., GE Healthcare, Genmab A/S, Genzyme Corporation, Geron Corporation, GlaxoSmithKline Plc, Groupe Lactalis, Hutchison 3G UK Limited, Janssen Pharmaceuticals, Inc., Nestlé SA, Publicis Groupe SA, Synthes Inc., The LEGO Group

To order this report: Drug_Delivery_Technology Industry: Central Nervous System Drug Delivery Specialists

Nicolas Bombourg
Reportlinker
Email: nicolasbombourg@reportlinker.com
US: (805)652-2626
Intl: +1 805-652-2626

SOURCE Reportlinker